Recent progress in tumour vaccine development
- 1 June 2003
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 12 (6) , 971-981
- https://doi.org/10.1517/13543784.12.6.971
Abstract
Immunotherapy offers an exciting opportunity to treat human cancer. Analysis of tumour-associated antigens is progressing. Assisted by animal models, such knowledge can be used to design tumour vaccines. By including adjuvants to increase immunogenicity, several tumours previously thought to be non-immunogenic are now considered targets for tumour vaccines. Newly acquired knowledge regarding dendritic cell physiology is incorporated in newly designed vaccines that are currently in Phase I and II trials. Such assessment provides the overall conclusion that tumour vaccines are safe and deserve a more prominent place in the sequel of treatments for human cancer.Keywords
This publication has 58 references indexed in Scilit:
- Toll-Like Receptor 4-Dependent Activation of Dendritic Cells by β-Defensin 2Science, 2002
- Efficient transduction and long-term retroviral expression of the melanoma-associated tumor antigen tyrosinase in CD34+ cord blood-derived dendritic cellsGene Therapy, 2002
- Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor LymphocytesScience, 2002
- Antitumor vaccination with HER-2-derived recombinant antigensInternational Journal of Cancer, 2002
- Inhibition of prostate‐specific membrane antigen (PSMA)‐positive tumor growth by vaccination with either full‐length or the C‐terminal end of PSMAInternational Journal of Cancer, 2002
- Generation of potent and specific cellular immune responses via in vivo stimulation of dendritic cells by pNGVL3-hFLex plasmid DNA and immunogenic peptidesGene Therapy, 2002
- Amino acid modifications in the wild type sequence p53 232-240 overcome the poor immunogenicity of this self tumour epitopeJournal of Peptide Science, 2002
- Antigenic and immunologic characterization of an allogeneic colon carcinoma vaccineClinical and Experimental Immunology, 2002
- Inducing Tumor Immunity through the Selective Engagement of Activating Fcγ Receptors on Dendritic CellsThe Journal of Experimental Medicine, 2002
- Rapid Induction of Tumor-specific Type 1 T Helper Cells in Metastatic Melanoma Patients by Vaccination with Mature, Cryopreserved, Peptide-loaded Monocyte-derived Dendritic CellsThe Journal of Experimental Medicine, 2002